Limitace účinnosti idarucizumabu při akutním renálním selhání – kazuistika

Investor logo

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English Limitations of idarucizumab efficacy in acute renal failure – a case report
Authors

RYCHLÍČKOVÁ Jitka TRÁVNÍČEK Tomáš JELÍNKOVÁ Tereza ŽÁK Jan

Year of publication 2023
Type Article in Periodical
Magazine / Source Klinicka Farmakologie a Farmacie
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.klinickafarmakologie.cz/pdfs/far/2023/02/08.pdf
Doi http://dx.doi.org/10.36290/far.2023.015
Keywords dabigatran; idarucizumab; acute renal failure; efficacy; limits
Description Idarucizumab, a monoclonal antibody fragment capable of binding dabigatran molecules in a 1 : 1 stoichiometric relationship, is a specific antidote for dabigatran. The dose of idarucizumab was estimated based on observed plasma concentrations of dabigatran to achieve immediate, complete, and sustained reversal of the anticoagulant effect of dabigatran. Currently, a single dose of 5 g intravenously is recommended. However, in certain situations, the capacity of idarucizumab may be exhausted, and dabigatran plasma concentrations may rise again within hours of initial administration. We illustrate one such situation with a patient with acute renal failure, where despite the administration of the second dose of idarucizumab, there was no sustained reversal of the effect of dabigatran. The availability of a specific antidote is an indisputable advantage of dabigatran over other direct anticoagulants. Its use needs to be critically evaluated in view of the limitations of its efficacy. This is especially true in patients with acute renal failure or very high plasma concentrations of dabigatran.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.